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Abstract
A simple reversed phase high performance liquid chromatographic method with diode array detector (HPLC-DAD)
has been developed and subsequently validated for the determination of fexofenadine hydrochloride (FEX) and its
related compounds; keto fexofenadine (Impurity A), meta isomer of fexofenadine (Impurity B), methyl ester of
fexofenadine (Impurity C) in addition to the methyl ester of ketofexofenadine (Impurity D). The separation was
based on the use of a Hypersil BDS C-18 analytical column (250 × 4.6 mm, i.d., 5 μm). The mobile phase consisted
of a mixture of phosphate buffer containing 0.1 gm% of 1-octane sulphonic acid sodium salt monohydrate and 1%
(v/v) of triethylamine, pH 2.7 and methanol (60:40, v/v). The separation was carried out at ambient temperature
with a flow rate of 1.5 ml/min. Quantitation was achieved with UV detection at 215 nm using lisinopril as internal
standard, with linear calibration curves at concentration ranges 0.1-50 μg/ml for FEX and its related compounds.
The optimized conditions were used to develop a stability-indicating HPLC-DAD method for the quantitative
determination of FEX and its related compounds in tablet dosage forms. The drugs were subjected to oxidation,
hydrolysis, photolysis and heat to apply stress conditions. Complete separation was achieved for the parent
compounds and all degradation products. The method was validated according to ICH guidelines in terms of
accuracy, precision, robustness, limits of detection and quantitation and other aspects of analytical validation.
Background
Fexofenadine, a, a-dimethyl-4-[1-hydroxy-4-[4-(hydro-
xydiphenyl-methyl)-1-piperidinyl] butyl]-benzene acetic
acid [1] (Figure 1) is the active carboxylic acid analogue
of the antihistamine terfenadine. It shares the histamine
H1 receptor antagonist and non-sedative properties of
the parent compound. This could be attributed to its
capability to exist in zwitter-ionic form so it cannot pass
through blood-brain barrier and therefore does not
cause sedation [2,3]. Fexofenadine is a second genera-
tion antihistamine drug useful to available treatments of
allergic diseases with a wide margin of safety [4,5]. FEX
displays some anti-inflammatory properties and it has
also another advantage as it lacks the cardiotoxic side
effects (fatal arrhythmia) associated with terfenadine
[2,3]. FEX is rapidly absorbed with a long duration of
action, making it suitable for once daily administration.
Thus, it fulfils the essential and desirable characteristics
of an ideal antihistamine, being responsible for the
improvement in quality of life of the patients with aller-
gic diseases [4,6].
There are several reports on liquid chromatographic
determination of FEX in biological fluids. Among which
are those using LC-MS/MS [7], ultraviolet detection [8]
and fluorescence detection [9]. Few methods reported
the quantitation of FEX in pharmaceutical dosage forms
using spectrophotometric methods [10], LC methods
with ultraviolet detection [11-13], and capillary electro-
phoresis [14,15].
It is reported in the BP that four main impurities may
be encountered along with FEX (para isomer). These
impurities are; impurity A (keto fexofenadine), impurity
* Correspondence: hadirrona@yahoo.com
1Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud
University, Riyadh 11495, P.O. Box 22452, Saudi Arabia
Full list of author information is available at the end of the article
Maher et al. Chemistry Central Journal 2011, 5:76
http://journal.chemistrycentral.com/content/5/1/76
© 2011 Maher et al; licensee Chemistry Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.B (meta-isomer of FEX), impurity C (methyl ester of
fexofenadine) and D (methyl ester of keto fexofenadine),
Figure 1 [16]. The BP describes two separate HPLC
methods for the determination of FEX and its four
related impurities. The first one utilizes b-cyclodextrin
modified silica (silica gel BC for chiral chromatography
R1) to test for impurity B while the other is based on an
isocratic elution using phenylsilyl silica gel column for
the analysis of FEX along with the other three impuri-
ties; A, C, D [16]. FEX is also official in the USP [17].
Two HPLC methods have also been described in which
one of the methods is used for the separation and deter-
mination of related compound-B using an expensive b-
cyclodextrin modified silica column (USP L45) and the
other method for the determination of both FEX and its
related compound A using a phenyl bonded column
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Figure 1 Structures of fexofenadine and its related compounds.
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Page 2 of 10(USP L11). The other two impurities C and D are not
official in the USP [17].
Literature survey revealed a few methods for the
quantitative determination of FEX along with its related
impurities A and/or B in bulk or pharmaceutical dosage
forms by HPLC with UV detection [18,19]. One work
[18] describes simultaneous determination of FEX and
its two impurities A and B using C8 column as station-
ary phase and a mobile phase comprising 1% triethyla-
mine phosphate (pH 3.7), acetonitrile and methanol in
the ratio 60:20:20 (v/v/v). In the other published work
[19], the separation between FEX and its related impur-
ity B depends on the use of C18 column. The mobile
phase was a mixture of buffer and acetonitrile contain-
ing b-cyclodextrin. None of these methods [18,19] deals
with impurities C and D.
However, the other impurities C (methyl ester of fexo-
fenadine) and D (methyl ester of keto fexofenadine) may
be encountered along with the parent drug FEX depend-
ing on the method of preparation (Figure 1). It was
reported that FEX was prepared through a process that
involves reduction of a compound of formula (II) and
isolation of FEX monohydrate in crystalline form. Suita-
ble reducing agents preferably sodium borohydride is
used to yield the sodium salt of FEX which is converted
t ot h ef r e eb a s eb yp Ha d j u s t m e n t .T h e no p t i o n a l l yc o n -
verting FEX free base to a pharmaceutically accepted salt.
A further method for the preparation of FEX comprises a
process involving the hydrolysis of a keto ester of formula
(V) to the corresponding keto acid of formula (II) and
subsequent reduction of the acid as described above
[20,21]. This gives the possibility of the existence of
impurities A and D, respectively along with the parent
FEX. Also, FEX could be produced by a simple hydrolysis
of the methyl ester of FEX (a compound of formula IV)
giving a chance for the existence of the parent methyl
ester, the so called “Impurity C” along with the parent
drug.
To our knowledge, no single method was reported for
the simultaneous determination of FEX and its related
compounds A, B, C and D (Figure 1). The objective of
this work was to develop an analytical HPLC procedure,
which would serve as reliable and rapid method for the
simultaneous determination of FEX and its four related
impurities A, B, C and D. This manuscript describes the
development and subsequent validation of an isocratic
reversed phase HPLC method with diode array detector
using C 18 column as stationary phase for the above
determination. Quantitation was achieved using lisinopril
(LIS) as internal standard. In the proposed HPLC
method, the four impurities were well separated from
FEX and eluted before 25 min run time. The stability-
indicating property of the proposed method was also
evaluated.
Experimental
Materials and Reagents
Samples of fexofenadine hydrochloride (FEX) and its
related compounds A, B, C and D along with the internal
standard (lisinopril, LIS) were kindly supplied by Drug
control centre, Riyadh, Saudi Arabia. All reagents used
were of analytical grade, namely: Methanol (Panreac Co.,
E.U.), 1-octane sulphonic acid sodium salt, ortho-phos-
phoric acid and triethylamine (BDH Laboratory Suppliers,
Poole, England). The water used was double glass distilled.
Phosphate buffer solutions (0.05 M) of different pH values
were tried.
Tablets of Telfast
® (Safani Aventis, Paris, France), 120
mg of active drug FEX, batch number: 0TOO757, were
obtained through local pharmacy.
Instrumentation and chromatographic conditions
The chromatographic system, Waters (Milford, MA
01757, USA) consisted of Waters 1525 Binary HPLC
Pump, Waters 2707 Autosampler fitted with a 20 μl sam-
ple loop and Waters Diode array detector with multiple
wavelength selector. The LC system is equipped with a
data handling system comprised of a Dell personal compu-
ter and empower 2 software. HPLC separations were per-
formed on a Hypersil BDS stainless-steel C-18 analytical
column (250 × 4.6 mm, i.d.) packed with 5 μm diameter
particles. The mobile phase was a mixture of an aqueous
phase and methanol in a ratio of 60: 40 (v/v). The aqueous
phase consisted of 0.05 M phosphate buffer containing 0.1
gm% of 1-octane sulphonic acid sodium salt monohydrate
and 1% (v/v) of triethylamine. The pH of the aqueous
phase was adjusted to pH 2.7 with orthophosphoric acid
solution (10%). The mobile phase was filtered through a
Millipore membrane filter (0.2 μm) from Nihon, Millipore
(Yonezawa, Japan), and was degassed before use. The flow
rate was 1.5 ml/min. The detection wavelength was set at
215 nm and at ambient temperature (25°C). The injection
volume was 20 μl. The quantitation was performed using
lisinopril as internal standard. The area ratio was calcu-
lated relative to the internal standard (LIS).
Standard solutions and Calibration Graphs
Stock solutions (50 mg%) of FEX and its related com-
pounds were prepared in methanol. These solutions were
further diluted with the mobile phase to obtain working
standard solutions of suitable concentrations (0.1-50 μg/
ml for both FEX and the four related substances). The
concentration of the internal standard was maintained at
30 μg/ml in each solution of FEX, used for validation stu-
dies. Triplicate 20-μl injections were made for each con-
centration and were chromatographed under the
chromatographic conditions mentioned above. Peak area
ratios were plotted against the corresponding concentra-
tions to obtain the calibration graph for each compound.
Maher et al. Chemistry Central Journal 2011, 5:76
http://journal.chemistrycentral.com/content/5/1/76
Page 3 of 10Forced Degradation of fexofenadine
In order to establish whether the proposed method was
stability-indicating, FEX was stressed under various con-
ditions to conduct forced degradation studies [22-24].
Peak purity test performed by photodiode array detector
was useful to investigate peak purity.
All degradation experiments were performed using 1 ml
of stock FEX solution (50 mg%). After exposing the drug
to the studied degradation conditions, suitable dilution
with the mobile phase was made to get drug concentration
of 50 μg/ml.
For acid and base-induced degradation, FEX sample
w a sh e a t e dw i t h2m lo f0 . 5NH C lo r0 . 5NN a O Hf o r
acid and base-induced degradation, respectively, at 80°C
for 4 hr and then neutralized to pH 7.0.
For oxidative degradation, FEX sample was separately
h e a t e da t8 0 ° Cf o r2h ru s i n g1m lo fe a c ho f3 %a n d
30% H2O2.
For photo degradations, two separate solutions of pure
FEX were used. One solution was exposed to ultraviolet
light (254 nm) for 8 hr, and the other was subjected to
direct daylight for up to one week.
Thermal degradation was also tested by placing the
drug powder in a thermostated oven at 80°C for 8 hr.
Tablet preparation
Ten Telfast
® coated tablets were weighed and powdered.
An accurate weight of the powder equivalent to 50.0 mg
of FEX was transferred into a 100 ml volumetric flask and
extracted with 60 ml methanol in an ultrasonic bath for
30 min. The solutions thus prepared were diluted to
volume with the same solvent then filtered. Suitable dilu-
tions with the mobile phase were made to prepare tablet
solutions containing 30 μg/ml of FEX. Lisinopril (LIS) was
added to the prepared solution so that its final concentra-
tion is 30 μg/ml. Solutions thus prepared were filtered
using 0.45-mm filters (Millipore, Milford, MA, USA) then
analyzed as mentioned under the construction of calibra-
tion graphs.
Results and discussion
Method development
In the current study, Hypersil BDS C18 column was evalu-
ated for the purpose of separation among the active drug
FEX and its four related impurities. A wavelength of
215 nm was selected for the simultaneous determination
of FEX and its four impurities with high sensitivity.
To optimize the LC assay conditions, the effects of
methanol percentage as well as the pH of the aqueous
phase, the inclusion of ion pairing reagent (1-octane sul-
phonic acid) and addition of triethylamine (TEA) to the
mobile phase were studied. The amphoteric nature of
FEX, due to the presence of alicyclic amine and carboxylic
acid moieties, contributes to the dramatic responses of the
drug peaks to moderate variations in chromatographic
conditions [13].
1-Octane sulphonic acid was added to the mobile phase
to improve the sharpness and symmetry of FEX peaks and
its related compounds. Its effect can be explained in that it
acts as anionic ion pairing reagent for bases. It results in
the formation of a neutral ion pair between the reagent
and basic analytes. This species then undergoes mass
transfer with the stationery phase and ideally leads to the
separation of the components. A concentration of 0.1 gm
% of 1-octane sulphonic acid in the aqueous phase was
found optimum and produced maximum sharpness and
symmetry of these peaks.
TEA not only provided the desired pH together with
orthophosphoric acid, but also prevented peak tailing of
the basic analyte, FEX, due to its silanol masking feature
[22] thus permitting the separation of FEX from its related
impurity B. TEA in acid medium can be used to block
residual silanol groups on the silica gel backbone of
bonded phase columns. This is useful for the analysis of
basic ionized compounds which might interact with these
silanols. In this respect, TEA is used to upset this undesir-
able interaction. A concentration of 1% (v/v) TEA in the
mobile phase was found optimum in increasing the sharp-
ness and decreasing the tailing of the measured peaks.
The percentage of the organic modifier in the mobile
phase had a significant effect on the retention behavior of
the studied compounds. A satisfactory separation of FEX
and its four related impurities with satisfactory resolution
and increased speed was obtained with a mobile phase
containing 40% methanol. At lower methanol concentra-
tions, separations occurred but with excessive tailing and
increased retention times. Increasing methanol concen-
tration led to loss of resolution and overlapping peaks.
For further optimization, 0.05 M phosphate buffers
(containing 0.1 gm%-octane sulphonic acid and 1% (v/v)
TEA) at different pH values (ranging from 2.5 to 8)
were tried as the aqueous phase along with 40% metha-
nol in the mobile phase. Interestingly very good separa-
tion was achieved on a C18 stationary phase with the
mobile phase in which the pH of the aqueous phase was
adjusted to 2.7. Finally the mobile phase consisting of
buffer (0.05 M sodium phosphate buffer containing 0.1
gm% 1-octane sulphonic acid and 1% (v/v) triethylamine
adjusted to pH 2.7): methanol in a ratio of (60:40, v/v)
at a flow rate of 1.5 ml/min was found appropriate
allowing adequate separation of the five compounds;
FEX and its four related impurities.
The typical chromatogram of FEX sample spiked with
the four related impurities recorded using the proposed
method is shown in Figure 2a. The method permitted
adequate resolution of the mixture components within
reasonable run-time. FEX was eluted at 10.716 min
while the four related impurities were eluted at
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Page 4 of 1011.987 min (impurity B), 14.013 min (impurity A),
16.530 min (impurity C) and the last eluted peak
at 21.230 min being for impurity D. System suitability
results of the developed method are presented in Table 1.
The chromatographic characteristics of the mixture sum-
marized indicate that the proposed HPLC method per-
mitted adequate resolution of the mixture’s components
(good resolution and selectivity values) within reasonable
run-time (suitable capacity factors). In addition, high col-
umn efficiency was indicated from the large number of
theoretical plates. The degree of peak asymmetry was
also evaluated using the tailing factor which did not
exceed the critical value (1.2) indicating acceptable
degree of peak asymmetry. Relative response factor (RRF)
of each impurity relative to FEX peak was also calculated
as mentioned in Table 1. It is the ratio of the peak
response per unit concentration for each impurity to the
peak response per unit concentration for the reference
compound (FEX) under the given analytical conditions
[18]. Since UV absorption spectra of these impurities
were similar to that of FEX, their RRF were nearly equal
to 1.0. In addition, low values of RSD of peak area of all
studied compounds indicate good precision.
For the detection of the presence of possible impurities in
bulk powder, a very high concentration of FEX (1000 μg/
ml) was injected. The impurities can be identified by
matching the UV spectrum and the retention times with
that of standards in addition to the spiking technique. A
typical chromatogram of this high concentration of FEX is
shown in Figure 2b, b’ and as can be seen only impurity B
was detected.
Method validation
The proposed HPLC method was validated in compli-
ance with ICH guidelines [23-25]. The following para-
meters were validated. Lisinopril (LIS) was used as
internal standard for the purpose of quantification of
FEX and its four related compounds, being eluted at
 
(B)   (A) 
 (C)    
(D)    
a) 
b) 
b`) 
(B)    
Figure 2 A typical chromatogram of a standard mixture of 50 μg/ml FEX and its four related impurities; impurity A (A), impurity B (B),
impurity C (C) and impurity D (D), each at a concentration of 25 μg/ml, a), a very high concentration of FEX (1000 μg/ml), b) of which
the y-axis was rescaled to view the possible presence of impurities in bulk powder, b’).
Maher et al. Chemistry Central Journal 2011, 5:76
http://journal.chemistrycentral.com/content/5/1/76
Page 5 of 107.117 min with sharp and symmetric peak. Other com-
pounds were tried as internal standards, e.g. atenolol,
losartan, carvedilol, simvastatin, atorvastatin and hydro-
chlorthiazide but none of them produced satisfactory elu-
tion relative to the peaks of FEX and its related
compounds.
Linearity
Linearity was checked by preparing standard solutions at
five different concentration levels of each of FEX and its
four related compounds ranging from 0.1-50 μg/ml
using a fixed concentration of 30 μg/ml LIS as internal
standard. The equation for the calibration curve of FEX
was y = 0.0527 x-0.025 (r = 0.9996, Sy/x = 0.0459, Sb =
0.0010 and Sa = 0.0219), y =0 . 0 4 9 9x+0.063, r = 0.9993
(impurity B), y =0 . 0 5 5 3x+0.078, r = 0.9992 (impurity
A), y = 0.0545 x-0.047, r = 0.9991 (impurity C) and y =
0.0498 x-0.084, r = 0.9995 (impurity D). High values of
correlation coefficients indicating good linearity.
Limit of detection and limit of quantitation
Limit of detection (LOD) is defined as the concentration
which has a signal-to-noise ratio of 3:1. For limit of
quantitation (LOQ), the ratio considered was 10:1 with
aR S Dv a l u el e s st h a n1 0 %[ 2 6 , 2 7 ] .U s i n gt h ep r o p o s e d
HPLC method, LOD and LOQ for FEX and its related
impurities were calculated and were found to be 0.02
and 0.05 μg/ml, respectively.
Accuracy
The accuracy of the method for assay determination was
checked at three concentration levels of FEX; 0.1, 10.0,
and 50 μg/ml (n = 3) for 3 consecutive days. Solutions
for the standard curves were prepared fresh every day.
The percentage recoveries are tabulated in Table 2.
Standard addition and recovery experiments were also
conducted to determine the accuracy of the present
method for the quantification of related compounds A,
B, C and D. The range of addition levels of impurities
to the parent compound was done at 0.15-0.75% of the
concentration (10 μg/ml) of the FEX [18]. The recovery
of each impurity was calculated from the slope and
intercept of the calibration curve of each impurity. The
mean recovery of the four impurities were found to be
in the range of 98.4-102% (Table 3) indicating high
degree of accuracy of the developed method.
Precision
System repeatability was determined by replicate applica-
tions and measurements of peak area for FEX. Method
repeatability was obtained from RSD % values obtained
by repeating the assay three times on the same day
(intra-day precision). Intermediate precision was assessed
Table 1 Chromatographic characteristics of FEX and its four related impurities (A-D) using the proposed HPLC method
Compound tR RRT N k a Rs Tf RRF RSD
(area precision)
FEX 10.72 - 4940 6.2 1.000 - 0.40
1.15 2.3
Impurity A 11.99 1.12 5900 7.10 1.033 1.04 0.54
1.19 3.52
Impurity B 14.01 1.31 6210 8.47 1.123 0.91 0.65
1.20 4.39
Impurity C 16.53 1.81 8398 10.17 1.009 0.90 0.52
1.31 7.54
Impurity D 21.23 2.00 9500 13.34 1.189 0.91 0.66
tR: Retention time in min.
RRT: Relative retention time, of each impurity relative to FEX peak.
K: Capacity factor. a: Selectivity, between each two successive peaks.
Rs :Resolution, between each two successive peaks. Tf :Tailing factor.
RRF: relative response factor of each impurity relative to FEX peak.
RSD: relative standard deviation for area of five injections (instrument precision)
Table 2 Precision and accuracy in the assay
determination of FEX using the proposed LC method
Day of analysis Spiked concentration
(μg/ml)
Mean recovery (%) ± RSD
a
Repeatability (Intra-day precision)
Day 1 0.1 101.5 ± 0.89
10 99.4 ± 0.49
50 101.2 ± 0.67
Day 2 0.1 103.8 ± 0.99
10 100.2 ± 0.67
50 101.8 ± 0.89
Day 3 0.1 102.4 ± 0.1.2
10 99.4 ± 0.59
50 100.7 ± 0.55
Intermediate precision (Inter-day precision)
0.1 102.5 ± 1.13
10 99.6 ± 0.46
50 101.23 ± 0.54
a Mean recovery (%) ± RSD of three determinations.
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day precision). The intra-and inter-day precision studies
for the determination of FEX was carried out at three dif-
ferent concentration levels of 0.1, 10.0, 50 μg/ml (n = 3).
However, precision studies for the related impurities
were carried out at concentration levels of 0.15, 5.0 and
7.5 μg/ml. The calculated values of RSD% for FEX and its
related impurities were calculated and mentioned in
Tables 2 and 3, respectively. The results indicated high
degree of repeatability and intermediate precision of the
proposed method.
Robustness
To evaluate the HPLC method robustness, a few para-
meters were deliberately varied. The parameters included
slight variation in methanol percentage in the mobile
phase (38, 40, 42), pH of the aqueous phase (2.5, 2.7, 2.9),
flow rate (1.3, 1.5, 1.7 ml/min), injection volume (19.5, 20,
20.5 μl), wavelength of detection (213, 215, 217), column
temperature (23, 25, 27°C) and methanol of different lots.
Robustness of the method was done at the same concen-
tration levels as those used for the evaluation of the preci-
sion. Insignificant differences in peak areas (RSD < 2%)
and slight variability in k values (RSD < 1.8%) were
observed for FEX and related impurities.
Specificity
Specificity is the ability of the method to accurately
measure the analyte response in the presence of all
potential sample components.
To demonstrate the specificity of the method, the
impurities discussed above (A-D) were added to pure
FEX sample and the mixture was analyzed for assay and
the results were compared with pure sample results.
Reproducibility was observed in both the cases (RSD <
2.0). The specificity of the HPLC method was also
assessed by the complete separation of FEX in presence
of its related impurities along with other parameters like
retention time (tR), capacity factor (k), tailing factor (Tf),
etc. (Table 1). The peaks obtained were sharp and had
clear baseline separation (Figure 2a).
Forced degradations
Accelerated degradation studies were carried out in
order to provide an evidence for the specificity of the
proposed method.
The chromatograms of the samples treated with acid,
base, hydrogen peroxide, photochemical and dry heat,
showed well separated peaks of pure FEX. Summary of
all degradation studies was mentioned in Table 4.
Acid- and base-induced degradation
FEX peak detected at about 10.7 min showed drug recov-
ery at the level of 82.51% and 89.54% from the acid and
base stressed samples, respectively. For acid-induced
degradation, three secondary degradation peaks were
detected at 17.48, 19.62 and 26.40 min. However, for base-
induced degradation, no degradation peaks were recorded
under the studied conditions (Figures 3b, c).
Hydrogen peroxide-induced degradation
The chromatogram of the FEX sample treated with 3 and
30% (v/v)H 2O2 showed a significant degradation of FEX
(% recovery were 89.73 and 22.01, respectively). A second-
ary degradation peak was detected at 11.83 min with only
30% H2O2.T h ep e a ko fH 2O2 did not interfere with the
analysis being eluted at 2.78 min (Figures 3d, e).
Photo degradation
Photodegradation of FEX was studied using direct daylight
(up to 1 week) and UV light (254 nm). No significant
degradation of FEX was reported after the exposure of
drug solutions to direct daylight for up to one week or to
UV light (254 nm) for up to 8 hrs (Figure 3f).
Thermal degradation
Heating the drug powder in a thermostated oven at 80°C
for 8 hr produced nearly no effect on FEX peak indicating
its stability to thermal degradation under the studied con-
ditions (Figure 3g).
The number of degradation products with their tR values
and % recovery of FEX were calculated and are given in
Table 4. The chromatographic peak purity tool was
applied to verify FEX peaks, showing 100% purity in all
cases. This was performed by calculating purity angle and
purity threshold for FEX peaks. In all cases, FEX peak was
defined as main peak since match angle was less than
match threshold and also as a pure peak since purity angle
was less than purity threshold under all forced tests. This
showed that FEX peak had no detectable impurity peaks
embedded in and are free of co-eluting degradation com-
pounds. Besides, it was observed that peaks of FEX present
appropriate resolution and base-line separation and they
were not affected by degradation. From the above results,
it is clear that the proposed method can be used as a stabi-
lity indicating method for determining the stability of FEX
in bulk and pharmaceutical formulations.
Table 3 Precision and accuracy of FEX related compounds using the proposed HPLC method
Impurity A Impurity B Impurity C Impurity D
Overall mean % recovery
a 101.5 102.0 101.9 98.4
Intra-day precision (RSD) 1.55 1.23 0.88 1.32
Inter-day precision (RSD) 1.78 1.56 1.20 1.67
aOverall mean % recovery of three different concentration level(1.5, 5.0, 7.5 μg/ml), (n = 9)
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% Recovery Purity angle Purity threshold Match angle Match threshold tR valuesof degradation products
Acid-induced degradation
(0.5 N HCl, 80°C, 4 hr)
82.51 0.130 0.347 0.069 1.079 17.48, 19.62, 26.40
Base-induced degradation
(0.5 N NaOH, 80°C, 4 hr)
89.54 0.145 0.425 0.081 1.105 -
Oxidative degradation 89.73 0.125 0.332 0.084 1.071 -
-3% H2O2
(80°C, 2 hr)
-30% H2O2
(80 s°C, 2 hr)
22.01 0.145 0.352 0.035 1.077 11.83
Photochemical degradation 98.89 0.121 0.341 0.111 1.076 -
-Direct daylight
(7 days)
-UV at 254 nm
(8 hr)
98.66 0.111 0.342 1.076 1.098 -
Thermal degradation
(80°C, 8 hr)
98.40 0.118 0.411 0.101 1.098 -
*FEX peak was defined as main peak since match angle was less than match threshold and also as pure peak since purity angle was less than purity threshold
under all forced tests.
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Figure 3 A typical chromatogram of a standard solution containing 50 μg/ml FEX, a) and and its corresponding acid degradation, b),
base-degradation, c), oxidative-degradation with 3% H2O2, d), oxidative-degradation with 30% H2O2, e), day light degradation, f) and
thermal degradation, g).
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The excipients present in pharmaceutical tablets of FEX
did not show any interference with FEX peak since no
excipients peaks appear in the chromatogram of the pre-
pared tablet (Figure 4).
Analysis stability
Stability of assay solutions Standard and sample solu-
tions containing 50.0 μg/ml of FEX were prepared and
stored at room temperature, protected from light, for
20 hr. They were then injected into the LC system. Since
no additional peaks were found in the chromatogram with
no reduction in the peak area, this indicates stability of
both standard and sample solutions for about 20 hr.
Mobile phase stability Moreover, mobile phase stability
was also checked. This was performed by eluting standard
and sample solutions containing 50.0 μg/ml of FEX using
fresh and aged mobile phase (left for 7 days). It was con-
cluded that mobile phase preparation was found to be
stable for about 7 days since aged mobile phase produced
equivalent chromatography and results to that obtained
with fresh mobile phase.
Application to commercial tablets
Using the proposed HPLC chromatographic method, assay
of FEX in tablets was carried out as described under the
experimental section. Five replicate determinations were
made. Satisfactory results were obtained and were in a
good agreement with the label claim (Table 5). The results
of determination of FEX in tablets obtained from the sug-
gested HPLC method were compared with those of a
reference LC method [16]. Moreover, to check the validity
of the proposed methods, the standard addition method
was applied by adding FEX to the previously analyzed
tablets. The results of analysis of the commercial tablets
and the recovery study (standard addition method) of FEX
(Table 5) suggested that there is no interference from any
excipients, which are normally present in tablets. Statistical
comparison of the results was performed with regard to
accuracy and precision using Student’s t-test and the var-
iance ratio F-tests at 95% confidence level (Table 5). Since
the calculated t- and F-values did not exceed the
theoretical ones, this indicated that there was no signifi-
cant difference between the two methods of analysis
[26,27]. A typical HPLC chromatogram shown in Figure 4
indicates that FEX and the internal standard are well sepa-
rated in the formulation sample and no impurities were
detected in the analyzed concentration level.
Conclusion
A simple, specific and accurate RP-LC method with a
photodiode array detector has been developed and vali-
dated for the analysis of fexofenadine HCl along with its
four related compounds; keto fexofenadine (Impurity A),
meta isomer of fexofenadine (Impurity B), methyl ester of
fexofenadine (Impurity C) in addition to the methyl ester
of ketofexofenadine (Impurity D). The method is very eco-
nomical, because it required neither the use of a chiral sta-
tionary phase nor addition of chiral additives to the
mobile phase; the inexpensive phosphate buffer, 1-octane
sulphonic acid, triethylamine in addition to methanol as
the organic modifier were used as the mobile phase along
w i t hw i t haC 1 8R P - L Cc o l u m n ;t h e s ea r ea v a i l a b l ei n
every chromatography laboratory. The developed method
was fully validated as per ICH guidelines [23-25]. The
method provides simple, accurate, precise and stability-
indicating assay for the determination of FEX along with
its four related compounds in bulk powder and pharma-
ceutical tablets, without interference from the excipients
and in the presence of acidic, alkaline, oxidative, thermal
and photolytic degradation products. All of the degrada-
tion products were well separated from the drug sub-
stances demonstrating the stability-indicating power of the
method. Thus the developed method is a stability-indicat-
ing assay that can be widely used for the routine analysis
of FEX and its related impurities, in bulk powder and
pharmaceutical tablets without any interference.
Abbreviations
HPLC: high-performance liquid chromatography; DAD: diode array detector;
BP: british pharmacopoeia; USP: united states pharmacopoeia; FEX:
Figure 4 A chromatogram of the prepared tablet solution
containing 30 μg/ml of each of FEX and the internal standard;
LIS.
Table 5 Determination of FEX in commercial tablets* by
the proposed LC method
Mean found ± RSD%
a
Proposed LC method Reference method [16]
98.97 ± 0.49 99.22 ± 1.07
F
b = 4.768
t
b = 0.992
Recovery
c
99.15 ± 0.65 99.33 ± 0.24
*Labelled to contain 120 mg FEX per tablet, batch number 0T00757.
a Mean and RSD% for five determinations
b Theoretical values of F and t for p = 0.05 and n = 5 are 6.39 and 2.31,
respectively.
c For standard addition of 50% at the nominal content (n = 5)
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Page 9 of 10fexofenadine; Impurity A: keto fexofenadine; Impurity B: meta isomer of
fexofenadine; Impurity C: methyl ester of fexofenadine; Impurity D: methyl
ester of keto fexofenadine; LIS: lisinopril; TEA: triethyl amine; ICH:
International Conference on Harmonization; UV: ultraviolet; LOD: limit of
detection; LOQ: limit of quantification; SD: standard deviation; RSD: relative
standard deviation; (tR): retention time; (k): capacity factor; (Tf): tailing factor.
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